AbbVie Inc.

AbbVie Inc.

49,840.00
ARS
+360.00
(+0.73%)
962.10EPS
43.90P/E
692.19TMarket Cap
Feb 03Next Earn

Total Valuation

ARS

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 carries a market capitalization of 692.19T, placing it among publicly traded companies globally. Its enterprise value stands at 799.17T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap692.19T
Enterprise Value799.17T

Important Dates

AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1's next confirmed earnings release is scheduled for February 3, 2027.

Earnings Date2/3/2027

Share Statistics

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 has 16.35B shares outstanding.

Shares Outstanding16.35B

Valuation Ratios

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 trades at a trailing price-to-earnings ratio of 43.90. The price-to-sales ratio is 6.88, and the price-to-book ratio stands at -99.07.

PE Ratio43.90
PS Ratio6.88
PB Ratio-99.07
P/TBV Ratio-4.58
P/FCF Ratio24.13
P/OCF Ratio22.60

Enterprise Valuation

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 trades at an EV/EBITDA multiple of 18.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 trades at an EV/FCF ratio of 24.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 799.17T versus a market cap of 692.19T, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.94
EV / EBITDA18.14
EV / EBIT24.69
EV / FCF24.64

Financial Position

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,782.79, indicating conservative leverage, while an interest coverage ratio of 9.70 demonstrates adequate ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.56
Debt / Equity-1,782.79
Debt / EBITDA2.80
Interest Coverage9.70

Financial Efficiency

ARS

These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) comes in at 24.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.88, useful for judging operating efficiency across full business cycles. The company generates approximately 1.77B in revenue per employee across its workforce of 57,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.39 indicates how many times AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)7.35
Return on Invested Capital (ROIC)24.06
Return on Capital Employed (ROCE)17.88
Revenue Per Employee1.77B
Employee Count57,000.00
Inventory Turnover3.39

Taxes

ARS

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 recorded 3.76T in income tax expense. That works out to an effective tax rate of 19.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 19.53T, leaving 15.77T in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax3.76T
Effective Tax Rate19.24

Stock Price Statistics

ARS

As of the close on November 16, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1's stock has gained approximately 43.63% over the past 52 weeks. The 50-day moving average sits at 44,398.80, while the 200-day moving average is 37,037.10.

52-Week Price Change43.63%
50-Day Moving Average44,398.80
200-Day Moving Average37,037.10

Income Statement

ARS

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 generated 100.64T in revenue and converted that into 15.77T in net income, yielding earnings per share of 962.10. EBITDA reached 44.06T, while operating income came in at 36.21T.

Revenue100.64T
Gross Profit74.19T
Operating Income36.21T
Pretax Income19.53T
Net Income15.77T
EBITDA44.06T
EBIT32.37T
Earnings Per Share (EPS)962.10

Balance Sheet

ARS

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 holds 16.42T in cash and equivalents against 123.34T in total debt, resulting in a net debt position of 106.91T. Total book value stands at -6.99T, with working capital of -8.57T providing operational flexibility.

Cash & Cash Equivalents16.42T
Total Debt123.34T
Net Debt106.91T
Equity (Book Value)-6.99T
Book Value Per Share-427.37
Working Capital-8.57T

Cash Flow

ARS

AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 produced 30.63T in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.86T in capital expenditures, free cash flow totaled 28.77T - equivalent to 1,760.03 per share.

Operating Cash Flow30.63T
Capital Expenditures-1.86T
Free Cash Flow28.77T
FCF Per Share1,760.03

Margins

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 posted a gross margin of 73.72, reflecting its pricing power and cost economics. The operating margin of 35.98 and net profit margin of 15.67 provide insight into operational efficiency.

Gross Margin73.72
Operating Margin35.98
Pretax Margin19.41
Profit Margin15.67
EBITDA Margin43.78

Dividends & Yields

ARS

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 paid dividends of 1,132.01 per share. The dividend payout ratio of 117.23 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.14, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.33, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 shareholders.

Dividend Per Share1,132.01
Payout Ratio117.23
Shareholder Yield0.33
FCF Yield4.14

Scores

As of September 30, 2026, AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 has an Altman Z-Score of 3.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.95